How Kerry tackles nutrition trends in women’s health, weight loss and longevity
The nutrition industry is undergoing a significant shift as companies increasingly prioritize clinical research to address long-standing gaps in women’s wellness, healthy aging and weight management. Kerry, a major player in the sector, is currently utilizing a robust pipeline of clinical trials to move beyond traditional product categories and offer targeted solutions for specific, underserved health needs.
By focusing on evidence-based outcomes, the company is attempting to provide scientific validation for products that support real-world health challenges. This approach signals a broader move toward transparency and clinical rigor in the consumer health space, where the goal is to improve the quality of life rather than merely marketing broad-spectrum supplements.
Addressing Underserved Needs in Women’s Health
Kerry is expanding its focus in women’s wellness to address conditions that have historically lacked sufficient commercial solutions. This includes developing support for mastitis—a condition impacting roughly one in three to one in two breastfeeding mothers—as well as products for polycystic ovary syndrome and fertility.
The company is also looking to innovate in the fertility space with a forthcoming product designed to support both men and women simultaneously. The use of the ingredient Sensoril ashwagandha has shown potential in reducing menopause-related symptoms such as hot flashes and sweating, providing a data-driven option for postmenopausal women looking to manage their health.
Extending the Health Span
A primary focus for the industry is the distinction between lifespan and health span—the number of years a person lives in good health. With the World Health Organization noting that some populations face over a decade of living with disability or illness, there is an urgent push to develop products that support the body’s biological processes as it ages.
Kerry is prioritizing randomized clinical trials specifically for populations over age 60. By moving away from simply repositioning existing products and toward dedicated research on immune health and cognitive function, the company aims to address the specific physiological realities of the elderly population. This includes aligning product development with the 14 hallmarks of aging.
Supporting New Weight Loss Therapies
The rise of GLP-1 weight loss medications has created a new category of consumer needs, particularly regarding gastrointestinal side effects. Rather than attempting to compete with these medications, the industry is identifying ways to support patients who experience bloating, diarrhea, or discomfort while on them.
Research into products like the BC30 probiotic and the Plenibiotic postbiotic suggests that targeted nutritional support can improve patient compliance. Clinical data indicates that these interventions helped 70% of a cohort of patients manage their gut issues, making it easier for them to continue their prescribed treatment regimens.
What Comes Next?
As the industry continues to invest in clinical trials, it is likely that more specialized products will emerge to bridge the gap between pharmaceutical interventions and daily nutrition. Analysts might expect a continued focus on “beauty-from-within” products, such as postbiotics that help retain skin moisture, alongside further research into cognitive health for aging populations. Should these clinical pipelines continue to yield positive results, consumers may see a transition toward more personalized health solutions that are specifically designed to address complex, age-related physiological changes.
Frequently Asked Questions
What is the primary goal of Kerry’s research into GLP-1 therapies?
The goal is to alleviate gastrointestinal side effects—such as bloating and diarrhea—to help patients continue their weight loss medication journey.
How is the company addressing the disparity between lifespan and health span?
By investing in randomized clinical trials specifically for adults over age 60 and focusing on the 14 hallmarks of aging to proactively support health during the later stages of life.
What is unique about the company’s upcoming fertility product?
It is designed as a single, world-first product intended to boost fertility rates in both men and women collectively.
How do you prioritize scientific research when choosing the health products you use in your daily life?